Successful management of unstable angina in a ravulizumab-treated patient with paroxysmal nocturnal hemoglobinuria

Ravulizumab is an anti-C5 antibody approved for treating paroxysmal nocturnal hemoglobinuria (PNH). In August 2019, a 77-year-old Japanese man with PNH, who had been on ravulizumab treatment for 2 years, was hospitalized for chest discomfort and malaise. Electrocardiography identified a right bundle...

Descripción completa

Detalles Bibliográficos
Autores principales: Takahashi, Hiroshi, Mori, Hirotaka, Fukatsu, Masahiko, Sano, Takahiro, Harada, Kayo, Oikawa, Masayoshi, Takeishi, Yasuchika, Kimura, Satoshi, Ohkawara, Hiroshi, Shichishima, Tsutomu, Ikezoe, Takayuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Fukushima Society of Medical Science 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9840890/
https://www.ncbi.nlm.nih.gov/pubmed/36130907
http://dx.doi.org/10.5387/fms.2022-16

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9840890/
https://www.ncbi.nlm.nih.gov/pubmed/36130907
http://dx.doi.org/10.5387/fms.2022-16

Ejemplares similares